WO2024133739 - AMYLIN RECEPTOR AGONISTS
National phase entry:
Publication Number
WO/2024/133739
Publication Date
27.06.2024
International Application No.
PCT/EP2023/087353
International Filing Date
21.12.2023
Title **
[English]
AMYLIN RECEPTOR AGONISTS
[French]
AGONISTES DU RÉCEPTEUR DE L'AMYLINE
Applicants **
NOVO NORDISK A/S
Inventors
JØRGENSEN, Cecilie Mia
KRUSE, Thomas
LAU, Jesper F.
Priority Data
22215958.4
22.12.2022
EP
18/512,512
17.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2611 | |
| EPO | Filing, Examination, Granting | 10264 | |
| Japan | Filing, Examination, Granting | 2171 | |
| South Korea | Filing, Examination, Granting | 2084 | |
| USA | Filing, Examination, Granting | 6390 |
Total:
23,520
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to a compound comprising an amylin receptor agonist. The invention also relates to a pharmaceutical composition, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical composition comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.[French]
L'invention concerne un composé contenant un agoniste du récepteur de l'amyline. L'invention concerne également une composition pharmaceutique contenant un tel composé, appropriée pour, mais sans s'y limiter, une administration orale. Le composé et la composition pharmaceutique le contenant peuvent être utilisés dans le traitement médical de sujets souffrant de surpoids, d'obésité et de comorbidités associées.